MedPlus Health Services Limited has announced its unaudited financial results for the quarter ended December 31, 2025, showcasing strong operational performance and continued growth momentum. The company's Board of Directors approved the quarterly results at their meeting held on January 30, 2026.

Financial Performance Highlights

The company delivered impressive financial results for Q3FY26, with consolidated revenue from operations reaching ₹18,061.18 million compared to ₹15,614.46 million in Q3FY25, representing a robust growth of 15.67%. Net profit after tax increased significantly by 26.00% to ₹577.88 million from ₹458.70 million in the corresponding quarter of the previous year.

Profitability and Margin Expansion

The company demonstrated strong operational efficiency with EBITDA reaching ₹1.60 billion in Q3FY26 compared to ₹1.10 billion in the corresponding quarter of the previous year. The EBITDA margin expanded significantly to 8.78% from 6.83%, reflecting improved cost management and operational leverage.

Nine-Month Performance

For the nine-month period ended December 31, 2025, the company maintained its growth trajectory with revenue from operations of ₹50,280.81 million compared to ₹46,264.44 million in the corresponding period of FY25, marking an 8.68% increase. Net profit for the nine-month period stood at ₹1,556.33 million, up from ₹989.13 million in the previous year, representing a substantial growth of 57.35%.

Segment-wise Performance

The retail segment remained the primary revenue contributor, generating ₹17,733.70 million in Q3FY26 compared to ₹15,338.87 million in Q3FY25. The diagnostic services segment contributed ₹326.67 million in revenue, up from ₹274.67 million in the previous year. The retail segment also delivered strong profitability with segment results of ₹641.30 million compared to ₹536.61 million in Q3FY25.

Corporate Actions and Regulatory Updates

The Board approved the allotment of 2,32,061 equity shares under the MedPlus Employees Stock Option Plan 2021 to eligible employees. The company clarified that this allotment is not material in nature. The statutory auditors B S R and Co. have expressed an unmodified opinion in their Limited Review Report for both standalone and consolidated financial results.

Labour Code Impact

The company has assessed the impact of the four Labour Codes notified by the Government of India on November 21, 2025. For the consolidated results, MedPlus recorded an incremental non-recurring impact of ₹70.59 million as employee benefits expense. The company continues to monitor developments and will provide appropriate accounting treatment as needed.

Standalone Performance

On a standalone basis, the company reported revenue from operations of ₹2,230.01 million in Q3FY26 compared to ₹1,767.93 million in Q3FY25, representing growth of 26.13%. Standalone net profit increased to ₹165.76 million from ₹93.69 million, marking a significant improvement of 76.95%.

MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a wholly-owned subsidiary, received a drug license suspension order from the Telangana Drugs Control Administration.

Suspension Details

The Assistant Director of Drugs Control Administration, Patancheru, Telangana, issued the suspension order for one of the subsidiary's stores. The affected outlet is situated at Kardanur Patancheru Shankarpalli Road in Telangana.

Regulatory Compliance

The suspension has been imposed under Rule 66(1) of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company has made this disclosure in compliance with SEBI Regulation 30, which mandates listed entities to inform exchanges about material events and regulatory actions.

Financial Impact

MedPlus Health Services has quantified the potential financial impact of this regulatory action. The company estimates a potential revenue loss of Rs 0.20 lacs due to the one-day suspension of the store's operations.

Disclosure Requirements

The company has fulfilled its disclosure obligations pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The information has been made available on the company's website and will also be accessible on BSE and NSE websites for stakeholder reference.